Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Oncology

(Chemo)resistance Is Futile

While late diagnosis remains a key reason for the dismal outcome of pancreatic ductal adenocarcinoma (PDAC), the fact that it is difficult to treat using non-surgical methods also presents a big problem. PDAC tumors are often resistant to chemotherapy; only two agents are currently approved to treat advanced disease. The first, gemcitabine, increases median survival by just over one month (from 4.41 to 5.65 months) compared with the previously used drug, 5-fluorouracil (1). Adding the second, erlotinib, has an even smaller effect – increasing survival by only one-third of a month (2). Despite the many Phase III trials conducted to improve the efficacy of chemotherapy – using everything from traditional chemotherapy to experimental targeted approaches – PDAC remains stubbornly resistant to treatment (3).

Why? Because very few patients ever experience a good response to chemotherapy, we know that PDAC’s resistance to treatment is primary (innate), rather than secondary (acquired) as in most other cancers – but what we haven’t known is what gives rise to this resistance. One research team from the University of Texas MD Anderson Cancer Center pointed the finger at the epithelial-to-mesenchymal transition (EMT). The EMT program plays a role in metastasis, but the researchers noticed that when cancer cells begin to migrate, they stop proliferating. Lead author Raghu Kalluri explained that “gemcitabine works primarily on cancer cells that are dividing or proliferating. When cancer cells suspend their proliferation – such as when they launch an EMT program – then anti-proliferation drugs like gemcitabine do not target them well,” (4).

To examine the role of EMT in PDAC, Kalluri and his colleagues generated mouse models of PDAC that featured a deletion of either Snail or Twist – two transcription factors responsible for the EMT program. Deleting either of those proteins had no effect on tumor pathology, invasion or metastasis, but it did increase cancer cell proliferation and gemcitabine sensitivity (5). “We found that the EMT program suppressed drug transporter and concentrative proteins, which inadvertently protected these cancer cells from anti-proliferative drugs, such as gemcitabine,” said Kalluri – so suppressing the influence of that program resulted in a stronger response to chemotherapy, including reduced tumor burden and significantly better survival. What does this mean for patients? No research has been conducted yet in humans, but the promising results in mice indicate that EMT suppression may be an intriguing target worthy of further investigation.

Mission: Impossible by Michael Schubert

Tapping a Rich Vein by Christopher Chapman

New Ab-ilities in Imaging by Michael Schubert

Surprising Subtypes by Michael Schubert

Friend or Foe? by Anne Marie Lennon

Breaching Cancer’s Defenses by Ingunn Stromnes

An Epigenetic Epiphany by Michael Schubert

Building a Better Mousetrap by Michael Schubert

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. HA Burris 3rd et al., “Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial”, J Clin Oncol, 15, 2403–2413 (1997). PMID: 9196156.
  2. MJ Moore et al., “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group”, J Clin Oncol, 25, 1960–1966 (2007). PMID: 17452677.
  3. PE Oberstein, KP Olive, “Pancreatic cancer: why is it so hard to treat?”, Therap Adv Gastroenterol, 6, 321–337 (2013). PMID: 23814611.
  4. MD Anderson, “Study reveals why chemotherapy may be compromised in patients with pancreatic cancer”, (2015). Available at: bit.ly/1MZsiCV. Accessed December 3, 2015.
  5. X Zheng et al., “Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer”, Nature, 527, 525–530 (2015). PMID: 26560028.
About the Author
Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register